[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367968-105":59,"doc-detail-367968-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","second-cancer-incidence-and-cause-specific-mortality-in-primary-gastrointestinal-non-hodgkin-lymphoma-survivors-a-population-based-cohort-study","Second Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors - A Population-Based Cohort Study","","Long-term outcomes in primary gastrointestinal non-Hodgkin lymphoma (PGI-NHL) survivors remain a clinical concern despite improved prognosis from therapeutic advances. This population-based cohort study evaluates patterns of second primary cancers and cause-specific mortality after PGI-NHL. It uses SEER-identified survivors (n=7556) and quantifies second cancer risk with standardized incidence ratios and absolute excess risks, while mortality is analyzed using proportional hazards distribution, Fine–Gray competing-risk regression, standardized mortality ratios, and absolute excess risks. Results report elevated overall second cancer and cause-specific mortality risks over decades.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/second-cancer-incidence-and-cause-specific-mortality-in-primary-gastrointestinal-non-hodgkin-lymphoma-survivors-a-population-based-cohort-study/367968/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/second-cancer-incidence-and-cause-specific-mortality-in-primary-gastrointestinal-non-hodgkin-lymphoma-survivors-a-population-based-cohort-study/367968.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the study evaluate in PGI-NHL survivors?","Question",{"text":113,"@type":114},"The study assesses patterns of second primary cancers and cause-specific mortality among survivors of primary gastrointestinal non-Hodgkin lymphoma.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were second cancer risks and mortality measured?",{"text":118,"@type":114},"Second cancer risks were evaluated using overall and site-specific standardized incidence ratios and absolute excess risks. Cause-specific mortality used proportional death distribution, Fine–Gray competing risk regression, standardized mortality ratios, and absolute excess risks.",{"name":120,"@type":111,"acceptedAnswer":121},"What key findings were reported about second primary cancers and mortality over time?",{"text":122,"@type":114},"During follow-up, survivors showed increased second primary cancer incidence with elevated site-specific signals. Mortality was also elevated, with excess mortality persisting beyond two decades.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367968,1790741568,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nSecond Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors: A Population-Based Cohort Study  \nJiahe Wu1,2 | Jiangping Yang3,4 | Yuxi Ding5 | Jili Wang6  | Xiaofei Cheng7 | Liangshun You8  | Feng Zhao1,4   \n1Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China | 2Graduate School, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China | 3Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China | 4Cancer Center of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China | 5School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China | 6Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China | 7Department of Colorectal Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China | 8Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China  \nCorrespondence: Liangshun You ([youliangshun@zju.edu.cn](youliangshun@zju.edu.cn)) | Feng Zhao ([zju_zhaofeng@zju.edu.cn](zju_zhaofeng@zju.edu.cn))  \nReceived: 13 August 2025 | Revised: 27 October 2025 | Accepted: 10 November 2025  \nFunding: This work was supported by the National Natural Science Foundation of China (82171890) .  \nKeywords: cause-specific mortality | primary gastrointestinal non-Hodgkin lymphoma | second primary cancers | standardized incidence ratio | standardized mortality ratio  \nABSTRACT  \nBackground: Therapeutic advances in primary gastrointestinal non-Hodgkin lymphoma (PGI-NHL) have improved patient prognosis but also raised concerns regarding long-term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause-specific mortality in PGI-NHL survivors.  \nMethods: A total of 7556 six-month survivors of PGI-NHL diagnosed between 1975 and 2015 were identified from the SEER database. SPC risks were evaluated using overall and site-specific standardized incidence ratios (SIRs) and absolute excess risks (AERs) relative to the US general population. Cause-specific mortality was assessed through proportional death distribution, the Fine–Gray competing risk regression model, standardized mortality ratios (SMRs), and AERs.  \nResults: During 75,914 person-years of follow-up, 1245 patients developed 1412 SPCs (SIR = 1.20, 95% CI = 1.14–1.27). Significantly elevated SIRs were observed for solid tumors (SIR = 1.16, 95% CI = 1.10–1.23) and hematolymphoid malignancies (SIR = 1.82, 95% CI = 1.49–2.19). Survivors with over 20 years of follow-up faced increased risks of oral cavity and pharyngeal cancers (SIR = 2.76, 95% CI = 1.11–5.69), gastric cancer (SIR = 3.12, 95% CI = 1.15–6.80), pancreatic cancer (SIR = 2.40, 95% CI = 1.10–4.55), and leukemia (SIR = 2.57, 95% CI = 1.17–4.87). The risk of developing SPCs decreased with increasing age at PGI-NHL diagnosis. Patients receiving combined chemoradiotherapy exhibited the highest overall SPC risk (SIR = 1.32, 95% CI = 1.09–1.58), particularly for gastric cancer (SIR = 8.20, 95% CI = 4.59–13.53) and pancreatic cancer (SIR = 3.15, 95% CI = 1.44–5.98) . A total of 4949 deaths occurred (SMR = 1.80, 95% CI = 1.75–1.85), with excess mortality persisting beyond two decades. The cumulative incidence of all-cause mortality was 28.9% at 5 years, 45.8% at 10 years, and 69.1% at 20 years post-diagnosis. Non-cancer causes posed a  \nThis is an open access article under the t","cbCaicpkcU8r2YbT","https://ap.wps.com/l/cbCaicpkcU8r2YbT","pdf",1852768,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What does the study evaluate in PGI-NHL survivors?\",\"answer\":\"The study assesses patterns of second primary cancers and cause-specific mortality among survivors of primary gastrointestinal non-Hodgkin lymphoma.\"},{\"question\":\"How were second cancer risks and mortality measured?\",\"answer\":\"Second cancer risks were evaluated using overall and site-specific standardized incidence ratios and absolute excess risks. Cause-specific mortality used proportional death distribution, Fine–Gray competing risk regression, standardized mortality ratios, and absolute excess risks.\"},{\"question\":\"What key findings were reported about second primary cancers and mortality over time?\",\"answer\":\"During follow-up, survivors showed increased second primary cancer incidence with elevated site-specific signals. Mortality was also elevated, with excess mortality persisting beyond two decades.\"}]","Second Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors - A Population-Based Cohort Study | PDF",1790173978,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/838186cf923cb27e5fbe6aad562347af.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2acdcc160c8e0c2d9d286b7a6cd9fa8e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5274ec61bc1428fea1fed7497a287b0a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d515f39be9e8f005a7e0c7f9777f64a4.webp",980,1287]